ExonHit, UMBI announce RNA splicing symposium

September 16, 2002

ROCKVILLE, Md.--ExonHit Therapeutics, the alternative splicing-based drug discovery company, in association with the University of Maryland Biotechnology Institute (UMBI), will present the first annual symposium on "RNA splicing in Human Pathology, 2002" September 24 at the Shady Grove Campus of the University System of Maryland, Rockville, MD.

The symposium, chaired by Dr. Adrian Krainer, Cold Spring Harbor Laboratories, will provide a forum to discuss advances and issues in the field of RNA splicing. For program, click on: http://www.exonhit.com/splicing2002/index.htm

"Splicing 2002" will focus on state-of-the-art concepts and mechanisms of alternative RNA splicing, with leading scientists providing insight on the impact of alternative splicing in the onset and progression of diseases. Since the completion of the human genome sequencing, alternative RNA splicing has gained recognition as a key process in gene expression. It is also now viewed as a major event controlling gene regulation, and protein functionality and diversity.

The luncheon speaker at Splicing 2002 will be UMBI President Dr. Jennie Hunter-Cevera, an innovative leader in biotechnology with extensive background both in academia and industry. The University of Maryland Biotechnology is a research branch of the University System of Maryland, designed to advance research, training and economic development in the biotechnology sector.

"As a pioneer in the analysis of alternative splicing and its applications to discover new drugs and diagnostics, ExonHit Therapeutics felt the need for an annual scientific event in this emerging field of genomics," commented Bruno Tocqué, CEO of the company. "We are very pleased that such high profile international researchers in alternative splicing will present at this event. We hope to provide every participant with a state-of-the-art overview of alternative splicing and its implications on human pathologies," said Tocqué.

UMBI consists of five research and education centers across the state. UMBI's Center for Advanced Research in Biotechnology--a center of excellence in the field of protein structure, function, and design--is located on the USM Shady Grove Campus, at the heart of Maryland's primary corridor of biotech firms.

Participation to Splicing 2002 is free of charge and reserved for a limited number of attendees. Media is welcomed.
ExonHit Therapeutics, which was founded in 1997, has its headquarters and laboratories in Paris, France and its US operations are based in Gaithersburg, Maryland. The Company has 70 employees worldwide and has raised a total of $42 million.

The University of Maryland Biotechnology Institute was mandated by the state of Maryland legislature in 1985 as a "new paradigm of state economic development in biotech-related sciences." With five major research and education centers across Maryland, UMBI is dedicated to advancing the frontiers of biotechnology. The five centers are the Center for Advanced Research in Biotechnology in Rockville; Center for Biosystems Research in College Park; and Center of Marine Biotechnology, Medical Biotechnology Center, and the Institute of Human Virology, all in Baltimore.

University of Maryland Biotechnology Institute

Related Biotechnology Articles from Brightsurf:

Cyanobacteria as "green" catalysts in biotechnology
Researchers from TU Graz and Ruhr University Bochum show in the journal ACS Catalysis how the catalytic activity of cyanobacteria, also known as blue-green algae, can be significantly increased.

Biotechnology to the rescue of Brussels sprouts
An international team has identified the genes that make these plants resistant to the pathogen that attacks crops belonging to the cabbage family all over the world.

UM professor co-authors report on the use of biotechnology in forests
University of Montana Professor Diana Six is one of 12 authors of a new report that addresses the potential for biotechnology to provide solutions for protecting forest trees from insect and pathogen outbreaks, which are increasing because of climate change and expanded global trade.

Faster genome evolution methods to transform yeast for industrial biotechnology
A research team led by Prof. DAI Junbiao at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, in collaboration with Prof.

New innovations in cell-free biotechnology
Professor Michael Jewett's new platform to conduct cell-free protein synthesis could lead to improved quality of manufactured protein therapeutics and biomaterials.

Silk 'micrococoons' could be used in biotechnology and medicine
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.

The end of biotechnology as we know it
More than 400 attendees from five continents discussed trends and improvements in biotechnology at the European Summit of Industrial Biotechnology (ESIB) in Graz/Austria and talked many topics like a dehumanized research process.

Biotechnology: A growing field in the developing world
A detailed new report surveys a broad cross-section of biotechnology work across developing countries, revealing steady growth in fields tied to human well-being worldwide.

China releases first report on biotechnology in developing countries
The first report on biotechnology in developing countries revealing an overall picture of their biotechnology growth and competitiveness was released on Nov.

Exclusive: Biotechnology leaders surveyed about impact of Trump presidency
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by Genetic Engineering & Biotechnology News showed that Trump's presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a 'brain drain' as foreign-born researchers educated in American universities will be more likely to leave.

Read More: Biotechnology News and Biotechnology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.